ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Limited is a clinical-stage biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, with a particular focus on Parkinsonian and other movement disorders. The company's mission is to create an alternate, healthier future for individuals living with these debilitating conditions by disrupting their disease trajectory. Headquartered in Melbourne, Australia, Alterity Therapeutics also maintains a presence in San Francisco, California, USA.

The company's lead drug candidate is ATH434, a small molecule therapy designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, such as alpha-synuclein, and to preserve neurons. ATH434 has completed Phase II clinical trials for Parkinson's disease and is currently in Phase II clinical trials (ATH434-201 and ATH434-202) for Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disorder. Alterity Therapeutics also operates a broad drug discovery platform aimed at generating patentable chemical compounds to address the underlying pathology of various neurological diseases.

In recent developments, Alterity Therapeutics received positive feedback from the U.S. Food and Drug Administration (FDA) in April 2026 regarding its chemistry, manufacturing, and control elements for the planned Phase 3 development program of ATH434 in MSA. An End-of-Phase 2 meeting with the FDA is anticipated for mid-2026, marking a critical step towards a pivotal Phase 3 trial. The company's leadership includes CEO Dr. David Stamler, with recent board and management appointments including Ann Cunningham as an Independent Non-Executive Director and Daniel O. Claassen as Chief Medical Advisor in early 2026. Alterity is positioned as a clinical-stage biotech preparing for late-stage development, with analysts maintaining a bullish outlook.